XBI trade ideas
XBI (SPDR S&P Biotech ETF) is Bull to at least ~134.37Prediction: XBI (SPDR S&P Biotech ETF) is Bull to at least ~134.37 (Resistance line)
Reason: The chart is filled with Bull Harmonic Patterns. From the "Gartley" pattern (recent), to the larger "Butterfly" pattern which gives the overall reversal, to the in between "Shark" Bull Pattern. Every timeline shows new bull patterns.
The Volume Flow is increasing, and the momentum is strong.
Currently, it is consolidating but the bull pressure is too strong. It will pass the next resistance of 130.40 and then reach the resistance of 134.40. (Momentum will probably continue afterwards).
XBI will complete upwards 26 period than go up 1 or 2 cyclesXBI (Small Cap Biotech Index) is due for 2 or 3 upwards movements (includes current wave). XBI moves in cycles of 2 or 3 (or 4 when it became overextended) and in between we have a 1, 1 pattern (it takes a break) where it goes up 1 sideways / 1 down, or 1 up / 1 down.
I predict it will complete the upwards 26 period and then go upwards for 1 or 2 more 26 candle periods (daily timeframe).
The pattern doesn't say if it is going to move for 2 or 3 but it shows that it can be one or the other.
In addition, I factor the current bullish signs for XBI which helps to support this theory.
Note: The stock GH is included but hidden in order to allow me to show the higher pattern. It just a way to scale up the chart.
Double Bottom RectangleXBI formed a double bottom. The bulls made a stand at this level. Appears to be in a rectangle which is a neutral pattern until a trendline is broken with a trend in that direction.
The top trendline of a rectangle is resistance. The bottom is support. It is a horizontal trading channel and price can bounce back and forth until a trendline is broken.
No recommendation.
SPDR Series Trust - SPDR S&P Biotech ETF is an exchange traded fund launched by State Street Global Advisors, Inc. The fund is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Biotechnology Select Industry Index, by using representative sampling technique. SPDR Series Trust - SPDR S&P Biotech ETF was formed on January 31, 2006 and is domiciled in the United States.
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). Benchmark: S&P Biotechnology Select Industry TR USD.
Top 10 Holdings
Intellia Therapeutics Inc
1.15%
Moderna Inc
1.12%
Cytokinetics Inc
0.98%
Celldex Therapeutics Inc
0.91%
Translate Bio Inc
0.90%
Arcus Biosciences Inc
0.87%
Veracyte Inc
0.85%
ChemoCentryx Inc
0.84%
Biohaven Pharmaceutical Holding Co Ltd
0.83%
Kymera Therapeutics Inc Ordinary Shares
Price rejected at Weekly Support...Good risk/reward to go longI opened a Collar trade on this.
Trade Management: Long put @115
Short Call @130 June 18th
Learn, Plan, Size and Manage.
This publish is not an investment advice. I am not an investment advisor. So, you are solely responsible for your actions on your money.
Should be scanning ETFsCome Monday going to look at a position in XBI (if it has not gone too far). Pulled back and spiked at the Weekly 50% Retracement that matches with prior price action. Stop needs to be just below the low of May 11th.
The industry for this ETF is Biotech. This should make Cathie Wood happy.
Closing (IRA): XBI June 18th 115 Short Put... for a .37/contract debit.
Comments: In for 1.50/contract (See Post Below), out for .37/contract here; 1.13 ($113) profit per contract with 21 days to go. It's still somewhat weak here, but implied volatility has crushed into sub-35, which is kind of my exchange-traded fund implied volatility cut-off.